Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 12/2016

01.06.2016 | Original Article

The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy

verfasst von: Shozo Okamoto, Tohru Shiga, Koichi Yasuda, Shiro Watanabe, Kenji Hirata, Ken-ichi Nishijima, Keiichi Magota, Katsuhiko Kasai, Rikiya Onimaru, Kazuhiko Tuchiya, Yuji Kuge, Hiroki Shirato, Nagara Tamaki

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to prospectively investigate reoxygenation in the early phase of fractionated radiotherapy and serial changes of tumoricidal effects associated with intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer (HNC) using F-18 fluoromisonidazole (FMISO) PET and F-18 fluorodeoxyglucose (FDG) PET.

Methods

Patients with untreated HNC underwent FMISO-PET and FDG-PET studies prospectively. A PET evaluation was conducted before each IMRT (Pre-IMRT), during IMRT (at 30 Gy/15 fr) (Inter-IMRT), and after completion of IMRT (70 Gy/35 fr) (Post-IMRT). FMISO-PET images were scanned by a PET/CT scanner at 4 h after the FMISO injection. We quantitatively analyzed the FMISO-PET images of the primary lesion using the maximum standardized uptake (SUVmax) and tumor-to-muscle ratio (TMR). The hypoxic volume (HV) was calculated as an index of tumor hypoxia, and was defined as the volume when the TMR was ≥ 1.25. Each FDG-PET scan was started 1 h after injection. The SUVmax and metabolic tumor volume (MTV) values obtained by FDG-PET were analyzed.

Results

Twenty patients finished the complete PET study protocol. At Pre-IMRT, 19 patients had tumor hypoxia in the primary tumor. In ten patients, the tumor hypoxia disappeared at Inter-IMRT. Another seven patients showed the disappearance of tumor hypoxia at Post-IMRT. Two patients showed tumor hypoxia at Post-IMRT. The FMISO-PET results showed that the reduction rates of both SUVmax and TMR from Pre-IMRT to Inter-IMRT were significantly higher than the corresponding reductions from Inter-IMRT to Post-IMRT (SUVmax: 27 % vs. 10 %, p = 0.025; TMR: 26 % vs. 12 %, p = 0.048). The reduction rate of SUVmax in FDG-PET from Pre-IMRT to Inter-IMRT was similar to that from Inter-IMRT to Post-IMRT (47 % vs. 48 %, p = 0.778). The reduction rate of the HV in FMISO-PET from Pre-IMRT to Inter-IMRT tended to be larger than that from Inter-IMRT to Post-IMRT (63 % vs. 40 %, p = 0.490). Conversely, the reduction rate of the MTV in FDG-PET from Pre-IMRT to Inter-IMRT was lower than that from Inter-IMRT to Post-IMRT (47 % vs. 74 %, p = 0.003).

Conclusions

Both the intensity and the volume of tumor hypoxia rapidly decreased in the early phase of radiotherapy, indicating reoxygenation of the tumor hypoxia. In contrast, the FDG uptake declined gradually with the course of radiotherapy, indicating that the tumoricidal effect continues over the entire course of radiation treatment.
Literatur
1.
2.
Zurück zum Zitat Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18–24.CrossRefPubMed Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18–24.CrossRefPubMed
3.
Zurück zum Zitat Gaertner FC, Souvatzoglou M, Brix G, Beer AJ. Imaging of hypoxia using PET and MRI. Curr Pharm Biotechnol. 2012;13:552–70.CrossRefPubMed Gaertner FC, Souvatzoglou M, Brix G, Beer AJ. Imaging of hypoxia using PET and MRI. Curr Pharm Biotechnol. 2012;13:552–70.CrossRefPubMed
4.
Zurück zum Zitat Rajendran JG, Krohn KA. F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. Semin Nucl Med. 2015;45:151–62.CrossRefPubMedPubMedCentral Rajendran JG, Krohn KA. F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. Semin Nucl Med. 2015;45:151–62.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Hatano T, Zhao S, Zhao Y, Nishijima K, Kuno N, Hanzawa H, et al. Biological characteristics of intratumoral [F-18]-fluoromisonidazole distribution in a rodent model of glioma. Int J Oncol. 2013;42:823–30.PubMedPubMedCentral Hatano T, Zhao S, Zhao Y, Nishijima K, Kuno N, Hanzawa H, et al. Biological characteristics of intratumoral [F-18]-fluoromisonidazole distribution in a rodent model of glioma. Int J Oncol. 2013;42:823–30.PubMedPubMedCentral
6.
Zurück zum Zitat Sato J, Kitagawa Y, Yamazaki Y, Hata H, Okamoto S, Shiga T, et al. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma. J Nucl Med. 2013;54:1060–5.CrossRefPubMed Sato J, Kitagawa Y, Yamazaki Y, Hata H, Okamoto S, Shiga T, et al. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma. J Nucl Med. 2013;54:1060–5.CrossRefPubMed
7.
Zurück zum Zitat Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–41.CrossRefPubMedPubMedCentral Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–41.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Rischin D, Peters L, Fisher R, et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02). J Clin Oncol. 2005;23:79–87.CrossRefPubMed Rischin D, Peters L, Fisher R, et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02). J Clin Oncol. 2005;23:79–87.CrossRefPubMed
9.
Zurück zum Zitat Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol, Biol, Phys. 1995;33:391–8.CrossRef Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol, Biol, Phys. 1995;33:391–8.CrossRef
10.
Zurück zum Zitat Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–60.PubMed Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–60.PubMed
11.
Zurück zum Zitat Wenzl T, Wilkens JJ. Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications. Radiat Oncol. 2011;6:171.CrossRefPubMedPubMedCentral Wenzl T, Wilkens JJ. Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications. Radiat Oncol. 2011;6:171.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol, Biol, Phys. 2002;54:921–7.CrossRef Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol, Biol, Phys. 2002;54:921–7.CrossRef
13.
Zurück zum Zitat Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging. 2006;33:44–53.CrossRefPubMed Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging. 2006;33:44–53.CrossRefPubMed
14.
Zurück zum Zitat Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol, Biol, Phys. 2007;68:291–300.CrossRef Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol, Biol, Phys. 2007;68:291–300.CrossRef
15.
Zurück zum Zitat Toma-Dasu I, Dasu A. Modelling tumour oxygenation, reoxygenation and implications on treatment outcome. Comput Math Methods Med. 2013;2013:141087.CrossRefPubMedPubMedCentral Toma-Dasu I, Dasu A. Modelling tumour oxygenation, reoxygenation and implications on treatment outcome. Comput Math Methods Med. 2013;2013:141087.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Cn Fatema Zhao S, Zhao Y, Yu W, Nishijima K, Yasuda K, Kitagawa Y, et al. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT. BMC Cancer. 2014;14:692.CrossRef Cn Fatema Zhao S, Zhao Y, Yu W, Nishijima K, Yasuda K, Kitagawa Y, et al. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT. BMC Cancer. 2014;14:692.CrossRef
17.
Zurück zum Zitat Petersen C, Eicheler W, Frömmel A, Krause M, Balschukat S, Zips D, et al. Proliferation and micromilieu during fractionated irradiation. of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol. 2003;79:469–77.CrossRefPubMed Petersen C, Eicheler W, Frömmel A, Krause M, Balschukat S, Zips D, et al. Proliferation and micromilieu during fractionated irradiation. of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol. 2003;79:469–77.CrossRefPubMed
18.
Zurück zum Zitat Harriss W, Bezak E, Yeoh E, Hermans M. Measurement of reoxygenation during fractionated radiotherapy in head and neck squamous cell carcinoma xenografts. Australas Phys Eng Sci Med. 2010;33:251–63.CrossRefPubMed Harriss W, Bezak E, Yeoh E, Hermans M. Measurement of reoxygenation during fractionated radiotherapy in head and neck squamous cell carcinoma xenografts. Australas Phys Eng Sci Med. 2010;33:251–63.CrossRefPubMed
19.
Zurück zum Zitat Schütze C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Zips D, et al. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. Radiother Oncol. 2014;111:81–7.CrossRefPubMed Schütze C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Zips D, et al. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. Radiother Oncol. 2014;111:81–7.CrossRefPubMed
20.
Zurück zum Zitat Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol, Biol, Phys. 2007;68:515–21.CrossRef Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol, Biol, Phys. 2007;68:515–21.CrossRef
21.
Zurück zum Zitat Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406–10.CrossRefPubMed Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406–10.CrossRefPubMed
22.
Zurück zum Zitat Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med. 2009;50:1020–7.CrossRefPubMed Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med. 2009;50:1020–7.CrossRefPubMed
23.
Zurück zum Zitat Narita T, Aoyama H, Hirata K, Onodera S, Shiga T, Kobayashi H, et al. Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports. Jpn J Clin Oncol. 2012;42:120–3.CrossRefPubMed Narita T, Aoyama H, Hirata K, Onodera S, Shiga T, Kobayashi H, et al. Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports. Jpn J Clin Oncol. 2012;42:120–3.CrossRefPubMed
24.
Zurück zum Zitat Tachibana I, Nishimura Y, Shibata T, Kanamori S, Nakamatsu K, Koike R, et al. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy. J Radiat Res. 2013;54:1078–84.CrossRefPubMedPubMedCentral Tachibana I, Nishimura Y, Shibata T, Kanamori S, Nakamatsu K, Koike R, et al. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy. J Radiat Res. 2013;54:1078–84.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Wiedenmann NE, Bucher S, Hentschel M, Mix M, Vach W, Bittner MI, et al. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. Radiother Oncol. 2015;117:113–7.CrossRefPubMed Wiedenmann NE, Bucher S, Hentschel M, Mix M, Vach W, Bittner MI, et al. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. Radiother Oncol. 2015;117:113–7.CrossRefPubMed
26.
Zurück zum Zitat Hoang JK, Das SK, Choudhury KR, Yoo DS, Brizel DM. Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. AJNR Am J Neuroradiol. 2013;34:1428–33.CrossRefPubMed Hoang JK, Das SK, Choudhury KR, Yoo DS, Brizel DM. Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. AJNR Am J Neuroradiol. 2013;34:1428–33.CrossRefPubMed
27.
Zurück zum Zitat Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol. 2005;50:2209–24.CrossRefPubMed Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol. 2005;50:2209–24.CrossRefPubMed
28.
Zurück zum Zitat Abolmaali N, Haase R, Koch A, et al. Two or four hour [18F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin. 2011;50:22–7.CrossRefPubMed Abolmaali N, Haase R, Koch A, et al. Two or four hour [18F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin. 2011;50:22–7.CrossRefPubMed
29.
Zurück zum Zitat Henriquesde Figueiredo B, Merlin T, de Clermont-Gallerande H, Hatt M, Vimont D, Fernandez P, et al. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas. Strahlenther Onkol. 2013;189:1015–9.CrossRef Henriquesde Figueiredo B, Merlin T, de Clermont-Gallerande H, Hatt M, Vimont D, Fernandez P, et al. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas. Strahlenther Onkol. 2013;189:1015–9.CrossRef
30.
Zurück zum Zitat Jakoby BW, Bercier Y, Conti M, Casey ME, Bendriem B, Townsend DW. Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol. 2011;56:2375–89.CrossRefPubMed Jakoby BW, Bercier Y, Conti M, Casey ME, Bendriem B, Townsend DW. Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol. 2011;56:2375–89.CrossRefPubMed
31.
Zurück zum Zitat Panin VY, Kehren F, Michel C, Casey M. Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging. 2006;25:907–21.CrossRefPubMed Panin VY, Kehren F, Michel C, Casey M. Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging. 2006;25:907–21.CrossRefPubMed
32.
Zurück zum Zitat Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 2013;54:201–7.CrossRefPubMed Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 2013;54:201–7.CrossRefPubMed
33.
Zurück zum Zitat Yasuda K, Onimaru R, Okamoto S, Shiga T, Katoh N, Tsuchiya K, et al. [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer. Int J Radiat Oncol, Biol, Phys. 2013;85:142–7.CrossRef Yasuda K, Onimaru R, Okamoto S, Shiga T, Katoh N, Tsuchiya K, et al. [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer. Int J Radiat Oncol, Biol, Phys. 2013;85:142–7.CrossRef
34.
Zurück zum Zitat Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55(6):884–90.CrossRefPubMed Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55(6):884–90.CrossRefPubMed
35.
Zurück zum Zitat Fatema CN, Zhao S, Zhao Y, Yu W, Nishijima K, Yasuda K, et al. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT. BMC Cancer. 2014;14:692.CrossRefPubMedPubMedCentral Fatema CN, Zhao S, Zhao Y, Yu W, Nishijima K, Yasuda K, et al. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT. BMC Cancer. 2014;14:692.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Halmos GB, Bruine Debruin L, Langendijk JA, van der Laan BF, Pruim J, Steenbakkers RJ. Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review. Clin Nucl Med. 2014;39:44–8.CrossRefPubMed Halmos GB, Bruine Debruin L, Langendijk JA, van der Laan BF, Pruim J, Steenbakkers RJ. Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review. Clin Nucl Med. 2014;39:44–8.CrossRefPubMed
Metadaten
Titel
The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy
verfasst von
Shozo Okamoto
Tohru Shiga
Koichi Yasuda
Shiro Watanabe
Kenji Hirata
Ken-ichi Nishijima
Keiichi Magota
Katsuhiko Kasai
Rikiya Onimaru
Kazuhiko Tuchiya
Yuji Kuge
Hiroki Shirato
Nagara Tamaki
Publikationsdatum
01.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3431-4

Weitere Artikel der Ausgabe 12/2016

European Journal of Nuclear Medicine and Molecular Imaging 12/2016 Zur Ausgabe